Novartis First-Generation Lung Cancer Drug Tweaked To Reduce Potential Side Effects
Thursday, June 20, 2013 - 11:10
in Health & Medicine
Medicinal Chemistry: Redesigned enzyme inhibitor designated as breakthrough therapy by FDA
Updated by artificial intelligence Sat, 3 Jan 2026, 15:40:35 UTC Learn more
- Tell your friends
- Get science news via